Back to Search Start Over

Pharmacological and Biological Targeting of FGFR1 in Cancer

Authors :
Shuai Fan
Yuxin Chen
Wenyu Wang
Wanting Xu
Mei Tian
Yuetong Liu
Yutong Zhou
Dan Liu
Qin Xia
Lei Dong
Source :
Current Issues in Molecular Biology, Vol 46, Iss 11, Pp 13131-13150 (2024)
Publication Year :
2024
Publisher :
MDPI AG, 2024.

Abstract

FGFR1 is a key member of the fibroblast growth factor receptor family, mediating critical signaling pathways such as RAS-MAPK and PI3K-AKT. which are integral to regulating essential cellular processes, including proliferation, differentiation, and survival. Alterations in FGFR1 can lead to constitutive activation of signaling pathways that drive oncogenesis by promoting uncontrolled cell division, inhibiting apoptosis, and enhancing the metastatic potential of cancer cells. This article reviews the activation mechanisms and signaling pathways of FGFR1 and provides a detailed exposition of the types of FGFR1 aberration. Furthermore, we have compiled a comprehensive overview of current therapies targeting FGFR1 aberration in cancer, aiming to offer new perspectives for future cancer treatments by focusing on drugs that address specific FGFR1 alterations.

Details

Language :
English
ISSN :
14673045 and 14673037
Volume :
46
Issue :
11
Database :
Directory of Open Access Journals
Journal :
Current Issues in Molecular Biology
Publication Type :
Academic Journal
Accession number :
edsdoj.09d94349025d4808995a33dec426c932
Document Type :
article
Full Text :
https://doi.org/10.3390/cimb46110783